Nonmyeloablative Stem Cell Transplantation With or Without Lenalidomide for Chronic Lymphocytic Leukemia (RV-CLL-PI-0294).

Trial Profile

Nonmyeloablative Stem Cell Transplantation With or Without Lenalidomide for Chronic Lymphocytic Leukemia (RV-CLL-PI-0294).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Allopurinol; Antithymocyte globulin; Bendamustine; Fludarabine; Rituximab
  • Indications Chronic lymphocytic leukaemia; Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 May 2016 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association (n = 38).
    • 29 May 2015 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top